by Tony Jones, CEO, One Nucleus
As everyone heads into the summer break with the sun shining and batteries in need of recharging, it is only natural that for many, thoughts turn to what is coming up after the vacation and what is on the wish list to achieve by the end of 2025.
As the first half of the year has demonstrated, from the optimism many entered JPM Week 2025 with at the start of January, described at Genesis 2024. to the challenging impact of the impending world events and political change, the unexpected can happen in the world of biotech. Whilst the funding and deal landscape remains difficult, particularly for early-stage companies, there have also been some notable UK achievements such as Isomorphic Labs, CellCentric, Maxion Therapeutics, NodThera and Owlstone Medical. Larger and fewer deals seem to be the tale of the year to date, but seeing success in others provides hope for those still on the fundraising and dealmaking road. The change in mood seemed palpable in the world’s leading life science ecosystem, Boston, between visits in April and again in June. An uncertain and confused April dynamic seemed to have been replaced with a much more resilient and focussed determination by the time the BIO Convention had landed in town.
Resilience and Connectivity
That sense of cohesion and resilience observed sector-wide, not just in Boston, is a factor of the people and mindsets involved, without doubt. That belief that the bear market environment will end and opportunity for growth will return dominates the entrepreneurial character. Similarly, adapting to be smarter and prepared for that time when funding rounds and deals begin to flow more smoothly is also an entrepreneurial trait. Applying the lessons shared with peers and making the right connections is key. And this is where the annual Genesis conference has excelled for the past 24 editions and is evolving to continue that success.
Genesis 2024 saw candid panel discussions, fireside chats and keynote presentations set out the good, bad and ugly of dealmaking, business development and emerging technology adoption challenges, providing the sort of grounding anyone operating in the sector would do well to heed. You can read the Genesis 2024 Review to get up to speed.
What’s Happening at the 25th Edition of Genesis?
Continuing its evolution to provide our network with the peer-to-peer insights, connections and opportunity awareness, Genesis 2025, taking place on Wednesday 3 December at 1 Wimpole Street, London, will include:
- A keynote programme with views and reviews of current trends, best practices and stakeholder perspectives.
- **NEW** Company Showcase providing up to 40 companies the opportunity to present their value propositions and plans.
- 1-2-1 partnering arranged via the conference app.
- An Exhibition Hall surrounding the busy networking and catering areas.
- Genesis Fringe satellite events on the preceding days and RESI London the following day provide complementary opportunities whilst in London.
Who will inspire you?
It is already pleasing to see speakers from the following organisations accepting the invitation to contribute to the programme:
1004 Venture Partners, Antikor, Aspire Biosciences, AstraZeneca, BioLizard, Cambridge Medixine, Carocell Bio, Clarivate, Constructive Bio, Deep Science Ventures, Discovery Park, Domainex, East Genomic Medicine Service Alliance Patient and Public Voice Panel, Eli Lilly, F.E.C. Bio, Five Alarm Bio, Harness Therapeutics, Hyper Recruitment Solutions, Ikarovec, Kuano, Laverock Therapeutics, LifeArc, Life Science Nation, Monument Therapeutics, MetalloBio, Mursla Bio, Oppilotech, PrecisionLife, Pulse InfoFrame, RNAvate, Serenatis Bio, Stevenage Bioscience Catalyst, Stratosvir, Thermo Fisher, trialmed, UCL Business, VasoDynamics, Withers & Rogers and more to come…
Maximise your return on investment
Whilst some are focussing on the impending holiday season, others are making the most of their opportunity to secure profile-raising opportunities by getting involved as a programme moderator, sponsoring one of the high-profile packages or booking their exhibition space. It may not be that the early bird always catches the target investor, but the early booker at Genesis certainly secures the prime visibility spots.
To secure your optimal visibility, do contact the One Nucleus Genesis Team at your earliest convenience to discuss the options available.
It’s all about the people
Frequently in the drive to be efficient and targeted in how we instigate and develop the next business lead, it is the most difficult factor to quantify or describe that is the difference between success and failure. Who you meet and what or who they know can be unpredictable, but one thing that is predictable is that most investors, technology acquirers, and service users source their new business leads through their trusted network. The people factor can play an enormous role, and, complementing the larger global investor and partnering conferences, Genesis has always played the role of both getting to know this ecosystem and getting known by this ecosystem. There is no more fitting time, perhaps, to take stock of the past year, set out your wishes and look ahead to success in the year to come whilst connecting with friends known and those you are yet to meet that December in London. The annual Genesis conference brings this once-a-year opportunity, and we look forward to seeing you getting involved.
https://www.genesisconference.com/
Photography by www.SimonCallaghanPhotography.com
